Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 07, 2018

SELL
$9.52 - $12.15 $1,904 - $2,430
-200 Closed
0 $0
Q1 2018

Apr 18, 2018

BUY
$6.7 - $12.95 $1,340 - $2,590
200 New
200 $2,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Independence Bank Of Kentucky Portfolio

Follow Independence Bank Of Kentucky and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Independence Bank Of Kentucky, based on Form 13F filings with the SEC.

News

Stay updated on Independence Bank Of Kentucky with notifications on news.